In advanced melanoma, for which immunotherapy data are the most mature, approximately 38% of patients present with a type I tumor microenvironment and are considered the group that largely benefits from single-agent anti–PD-1/L1 blockade (36). The gene discussed is PDCD1; the disease is melanoma.